SG11201407518SA - Process for the preparation of rivaroxaban - Google Patents
Process for the preparation of rivaroxabanInfo
- Publication number
- SG11201407518SA SG11201407518SA SG11201407518SA SG11201407518SA SG11201407518SA SG 11201407518S A SG11201407518S A SG 11201407518SA SG 11201407518S A SG11201407518S A SG 11201407518SA SG 11201407518S A SG11201407518S A SG 11201407518SA SG 11201407518S A SG11201407518S A SG 11201407518SA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- rivaroxaban
- preparation
- vihar
- palam
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pens And Brushes (AREA)
- Orthopedics, Nursing, And Contraception (AREA)
- Adornments (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN1591DE2012 | 2012-05-24 | ||
| PCT/IB2013/054280 WO2013175431A1 (en) | 2012-05-24 | 2013-05-23 | Process for the preparation of rivaroxaban |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201407518SA true SG11201407518SA (en) | 2014-12-30 |
Family
ID=54193702
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201407518SA SG11201407518SA (en) | 2012-05-24 | 2013-05-23 | Process for the preparation of rivaroxaban |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20150133657A1 (sl) |
| EP (1) | EP2855465A1 (sl) |
| IN (1) | IN2014DN10209A (sl) |
| SG (1) | SG11201407518SA (sl) |
| WO (1) | WO2013175431A1 (sl) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016150937A1 (en) | 2015-03-25 | 2016-09-29 | Lonza Ltd | Method for preparation of thiophenecarbonyl chlorides |
| WO2016199027A1 (en) * | 2015-06-08 | 2016-12-15 | Mehta Api Pvt. Ltd. | An improved process for preparation of rivaroxaban |
| EP3325476B1 (en) * | 2015-11-04 | 2018-09-26 | Lonza Ltd | Method for preparation of thiophene-2-carbonyl chlorides |
| WO2023088229A1 (zh) * | 2021-11-17 | 2023-05-25 | 浙江华海药业股份有限公司 | 一种利伐沙班的合成方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUP0004388A3 (en) | 1997-11-07 | 2001-10-29 | Upjohn Co | Process for the preparation of oxazolidinones, intermediates and preparation thereof |
| DE19962924A1 (de) * | 1999-12-24 | 2001-07-05 | Bayer Ag | Substituierte Oxazolidinone und ihre Verwendung |
| DE10300111A1 (de) * | 2003-01-07 | 2004-07-15 | Bayer Healthcare Ag | Verfahren zur Herstellung von 5-Chlor-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid |
| DE10322469A1 (de) | 2003-05-19 | 2004-12-16 | Bayer Healthcare Ag | Heterocyclische Verbindungen |
| DE102007032347A1 (de) | 2007-07-11 | 2009-01-15 | Bayer Healthcare Ag | Aminoacyl-Prodrugs |
| EP2354128A1 (en) * | 2010-02-10 | 2011-08-10 | Sandoz Ag | Method for the preparation of rivaroxaban |
-
2013
- 2013-05-23 SG SG11201407518SA patent/SG11201407518SA/en unknown
- 2013-05-23 IN IN10209DEN2014 patent/IN2014DN10209A/en unknown
- 2013-05-23 WO PCT/IB2013/054280 patent/WO2013175431A1/en active Application Filing
- 2013-05-23 US US14/400,696 patent/US20150133657A1/en not_active Abandoned
- 2013-05-23 EP EP13734188.9A patent/EP2855465A1/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| EP2855465A1 (en) | 2015-04-08 |
| WO2013175431A1 (en) | 2013-11-28 |
| US20150133657A1 (en) | 2015-05-14 |
| IN2014DN10209A (sl) | 2015-08-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201804398XA (en) | Method for producing rna molecule compositions | |
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201804758QA (en) | Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab | |
| SG11201408385TA (en) | Methods of detecting diseases or conditions | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201407546QA (en) | Novel ring-substituted n-pyridinyl amides as kinase inhibitors | |
| SG11201408821SA (en) | Selective pi3k delta inhibitors | |
| SG11201407200TA (en) | Liquid formulation | |
| SG11201407486PA (en) | Compositions and methods for modulating utrn expression | |
| SG11201900772YA (en) | Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors | |
| SG11201803169WA (en) | Cellulase variants and polynucleotides encoding same | |
| SG11201901834WA (en) | Micrornas as biomarkers for endometriosis | |
| SG11201408261UA (en) | Syringe | |
| SG11201908640TA (en) | Pyrrolidinones and a process to prepare them | |
| SG11201407859YA (en) | Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists | |
| SG11201408646VA (en) | Dimeric protein with triple mutations | |
| SG11201407037UA (en) | Catechol o-methyltransferase activity inhibiting compounds | |
| SG11201408318RA (en) | Compositions and methods for transmucosal absorption | |
| SG11201408251SA (en) | A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota | |
| SG11201408750VA (en) | NOVEL FUSED PYRIDINE DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS | |
| SG11201810429UA (en) | Anti-cd19 antibody formulations | |
| SG11201407184PA (en) | Process for preparation of optically pure and optionally substituted 2- (1 -hydroxy- alkyl) - chromen - 4 - one derivatives and their use in preparing pharmaceuticals | |
| SG11201408224SA (en) | Novel ruthenium complexes, their use in the metathesis reactions, and a process for carrying out the metathesis reaction | |
| SG11201408037SA (en) | Humanized anti-trka antibodies with amino acid substitutions |